Independent Test Assessment Program (ITAP)

The National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative has established the Independent Test Assessment Program (ITAP) in order to accelerate regulatory review and availability of high-quality, accurate, and reliable over-the-counter COVID-19 tests to the public.  

The U.S. Department of Health and Human Services will prioritize new over-the-counter test applications that have the potential for manufacturing at significant scale. The goal is to accelerate the availability of high-quality, accurate, and reliable over-the-counter tests to the public as quickly as possible. 

For more information about this opportunity, please see the Point-of-Care Technology Research Network (POCTRN) website

    ITAP Tests Produced Per Month

    Data Updated: 06/30/2022


    Description: Number of tests produced per month are manufacturing capability and includes over the counter (OTC) tests in the Independent Test Assessment Program (ITAP).


    Send inquiries to

    Related News

    December 29, 2021
    side view of woman using nasal swab
    NIH RADx Tech Independent Test Assessment Program provides support for FDA authorization of two rapid at-home COVID-19 tests.
    October 25, 2021
    hands holding COVID test
    NIH is investing $70 million from the American Rescue Plan to help bring more high-quality, at-home tests onto the market in the U.S. in coordination with the FDA. NIH’s new Independent Test Assessment Program (ITAP) will establish an accelerated pathway to support FDA evaluation of tests with potential for large-scale manufacturing.

    Explore More

    There is so much more to explore at NIBIB.

    Health Topics

    Research Topics